technical analysis

The company is still behind the times and bleeding cash.
Many charts in the sector look similar, so an ETF may be the way to go.
Monday's lack of symmetry puts this area back in play.
This was the best breadth reading we've seen in two months. 
It's pretty clear you can have your cake here and eat it too.
Here's how I would trade it. Also, let's revisit Monsanto.
I'm targeting this key area on the Es.
The rally likely wasn't a one-off, but it won't be smooth sailing.
Symmetry can help you define risk in the marketplace.
If an edge is to be given, it should go to the bears.

Columnist Conversations

Europe should be in focus today. Escalating tensions in Ukraine triggered by new Russian aggression is increa...
the alibaba ipo date currently sept 16 or sept 23. that ipo is a money hog. thus stock-selling ahead of that i...
If this market has taught us one thing over the past 5 years, it has been to not be dogmatic in our views. Th...
Is this the biotech revolution or the biotech bust? View Small Cap Biotechs Like Never Before: Transparency is...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.